Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2005.03.7333 on August 14 2006

Journal of Clinical Oncology, Vol 24, No 26 (September 10), 2006: pp. 4285-4292
© 2006 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goecke, T.
Right arrow Articles by Moeslein, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goecke, T.
Right arrow Articles by Moeslein, G.

Genotype-Phenotype Comparison of German MLH1 and MSH2 Mutation Carriers Clinically Affected With Lynch Syndrome: A Report by the German HNPCC Consortium

Timm Goecke, Karsten Schulmann, Christoph Engel, Elke Holinski-Feder, Constanze Pagenstecher, Hans K. Schackert, Matthias Kloor, Erdmute Kunstmann, Holger Vogelsang, Gisela Keller, Wolfgang Dietmaier, Elisabeth Mangold, Nicolaus Friedrichs, Peter Propping, Stefan Krüger, Johannes Gebert, Wolff Schmiegel, Josef Rueschoff, Markus Loeffler, Gabriela Moeslein

From University Hospital, Heinrich-Heine-University, Institute of Human Genetics and Department of Surgery, Düsseldorf; Ruhr-University Bochum, Department of Medicine and Institute of Human Genetics; St Josefs-Hospital Bochum-Linden, Bochum; University Leipzig, Institute of Medical Informatics, Statistics and Epidemiology, Leipzig; Ludwig-Maximilian-University, Institute of Medical Genetics; Technical University, Department of Surgery and Institute of Pathology, Munich; University Hospital, Institute of Human Genetics and Institute of Pathology, Bonn; University of Technology, Department of Surgical Research, Dresden; University Hospital, Department of Molecular Pathology, Institute of Pathology, Heidelberg; University Regensburg, Institute of Pathology, Regensburg; and the Klinikum Kassel, Institute of Pathology, Kassel, Germany

Address reprint requests to Timm Goecke, MD, Department of Human Genetics, Heinrich-Heine-Universität, Moorenstrasse 5, D-40225 Düsseldorf; e-mail: goecke{at}uni-duesseldorf.de

Purpose: Lynch syndrome is linked to germline mutations in mismatch repair genes. We analyzed the genotype-phenotype correlations in the largest cohort so far reported.

Patients and Methods: Following standard algorithms, we identified 281 of 574 unrelated families with deleterious germline mutations in MLH1 (n = 124) or MSH2 (n = 157). A total of 988 patients with 1,381 cancers were included in this analysis.

Results: We identified 181 and 259 individuals with proven or obligatory and 254 and 294 with assumed MLH1 and MSH2 mutations, respectively. Age at diagnosis was younger both in regard to first cancer (40 v 43 years; P < .009) and to first colorectal cancer (CRC; 41 v 44 years; P = .004) in MLH1 (n = 435) versus MSH2 (n = 553) mutation carriers. In both groups, rectal cancers were remarkably frequent, and the time span between first and second CRC was smaller if the first primary occurred left sided. Gastric cancer was the third most frequent malignancy occurring without a similarly affected relative in most cases. All prostate cancers occurred in MSH2 mutation carriers.

Conclusion: The proportion of rectal cancers and shorter time span to metachronous cancers indicates the need for a defined treatment strategy for primary rectal cancers in hereditary nonpolyposis colorectal cancer patients. Male MLH1 mutation carriers require earlier colonoscopy beginning at age 20 years. We propose regular gastric surveillance starting at age 35 years, regardless of the familial occurrence of this cancer. The association of prostate cancer with MSH2 mutations should be taken into consideration both for clinical and genetic counseling practice.

published online ahead of print at www.jco.org on August 14, 2006.

Supported by the Deutsche Krebshilfe (German Cancer Aid).

T.G. and K.S. contributed equally to this work.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.




This article has been cited by other articles:


Home page
GutHome page
G L ten Kate, J H Kleibeuker, F M Nagengast, M Craanen, A Cats, F H Menko, and H F A Vasen
Is surveillance of the small bowel indicated for Lynch syndrome families?
Gut, September 1, 2007; 56(9): 1198 - 1201.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
A Gylling, W M Abdel-Rahman, M Juhola, K Nuorva, E Hautala, H J Jarvinen, J-P Mecklin, M Aarnio, and P Peltomaki
Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study
Gut, July 1, 2007; 56(7): 926 - 933.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online